Virtual Oral Presentation

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with NRG1 rearrangements

Presenting Author: Igor Odintsov, MD; Memorial Sloan Kettering Cancer Center

Event Websitehttps://event.eortc.org/ena2020/
Access: Free with registration
Session Title: Next Generation Targeted Therapies A
Saturday, October 24th, 22:00 – 23:20 CEST (4 PM – 5:20PM EDT), Channel 1

Spotlight on data:
Seribantumab in preclinical NRG1 fusion models